• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Immunol . Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood

tetano

Editor, Senior Moderator
Mol Immunol


. 2022 Mar 4;145:17-26.
doi: 10.1016/j.molimm.2022.03.004. Online ahead of print.
Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood


Josefine Persson[SUP] 1 [/SUP], Björn Andersson[SUP] 2 [/SUP], Suzanne van Veen[SUP] 3 [/SUP], Mariëlle C Haks[SUP] 3 [/SUP], Ogonna Obudulu[SUP] 4 [/SUP], Sara Torkzadeh[SUP] 4 [/SUP], Tom H M Ottenhoff[SUP] 3 [/SUP], Nelly Kanberg[SUP] 5 [/SUP], Magnus Gisslén[SUP] 5 [/SUP], Lars-Magnus Andersson[SUP] 5 [/SUP], Ali M Harandi[SUP] 6 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes mild symptoms in the majority of infected individuals, yet in some cases it leads to a life-threatening condition. Determination of early predictive biomarkers enabling risk stratification for coronavirus disease 2019 (COVID-19) patients can inform treatment and intervention strategies. Herein, we analyzed whole blood samples obtained from individuals infected with SARS-CoV-2, varying from mild to critical symptoms, approximately one week after symptom onset. In order to identify blood-specific markers of disease severity status, a targeted expression analysis of 143 immune-related genes was carried out by dual-color reverse transcriptase multiplex ligation-dependent probe amplification (dcRT-MLPA). The clinically well-defined subgroups of COVID-19 patients were compared with healthy controls. The transcriptional profile of the critically ill patients clearly separated from that of healthy individuals. Moreover, the number of differentially expressed genes increased by severity of COVID-19. It was also found that critically ill patients can be distinguished by reduced peripheral blood expression of several genes, which most likely reflects the lower lymphocyte counts. There was a notable predominance of IFN-associated gene expression in all subgroups of COVID-19, which was most profound in critically ill patients. Interestingly, the gene encoding one of the main TNF-receptors, TNFRS1A, had selectively lower expression in mild COVID-19 cases. This report provides added value in understanding COVID-19 disease, and shows potential of determining early immune transcript signatures in the blood of patients with different disease severity. These results can guide further explorations to uncover mechanisms underlying immunity and immunopathology in COVID-19.

Keywords: COVID-19; Gene expression; Immune response; SARS-CoV-2; dcRT-MLPA.
 
Back
Top Bottom